Journey Medical Corporation (NASDAQ:DERM) Given Average Recommendation of “Hold” by Analysts

Shares of Journey Medical Corporation (NASDAQ:DERM) have received a consensus rating of “Hold” from the five brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.1667.

A number of brokerages recently issued reports on DERM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Journey Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, October 13th.

Journey Medical Trading Down 2.6%

Shares of DERM stock opened at $7.92 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.42 and a quick ratio of 1.12. The company has a market cap of $214.95 million, a price-to-earnings ratio of -22.63 and a beta of 0.80. Journey Medical has a 1 year low of $3.54 and a 1 year high of $9.40. The firm has a fifty day moving average price of $7.99 and a 200-day moving average price of $7.47.

Journey Medical (NASDAQ:DERM) last released its earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $17.63 million for the quarter, compared to analysts’ expectations of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%. As a group, equities analysts predict that Journey Medical will post -1.02 earnings per share for the current year.

Institutional Trading of Journey Medical

Several institutional investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey bought a new position in Journey Medical in the 2nd quarter worth approximately $29,000. Bank of America Corp DE lifted its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after buying an additional 4,048 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Journey Medical during the second quarter worth $36,000. JPMorgan Chase & Co. bought a new position in shares of Journey Medical during the second quarter worth $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Journey Medical during the second quarter valued at $48,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.